

ECONOMIC AND FUND REVIEW

Markets breathed a sigh of relief in November, as positive results from three vaccine trials, pointed towards economies reopening. This overshadowed the worsening picture of rising daily new cases, with much of Europe and the US tightening restrictions. Joe Biden's victory over Donald Trump in the US election was also well received. But with republicans likely to maintain control of the senate, Biden's powers to raise taxes will be limited, as will the potential for a large fiscal stimulus package. Against this backdrop world equity markets reached new highs, with the sectors hardest hit by coronavirus, rebounding strongly. Oil was also up markedly on the reassessment of growth rates, while safe haven assets such as bonds and gold retreated.

Sarasin Responsible Global Equity GBP Hedged fund was the key driver of performance this month, underpinned by a strong recovery in consumer discretionary (think retail and leisure) and financial companies. These sectors were boosted by the prospect of economies reopening and normal activities resuming. Aside from the vaccine news, Zebra Technologies (whose products and technology allow the digital tracking of goods and inventory) also contributed to performance - reporting positive third quarter results, underpinned by continued demand for automating workflows. By contrast, the more defensive companies in SRGE and those boosted by lockdowns, weighed on performance. This meant Home Depot and Amazon were towards the bottom of the leader board, along with digital infrastructure specialist Equinix.

Vontobel's Sustainable Emerging Markets Leaders fund also performed well this month. Emerging Markets have suffered disproportionately from the pandemic and many investors pulled back from these regions at the start of the crisis. The prospect of a readily available vaccine, saw record investment back into EM economies.

Sarasin Responsible Corporate Bond performed well in the month, outperforming its benchmark, thanks to a higher exposure to banks and insurers.

While the vaccine news and passage of the US election boosted riskier assets, it dented the performance of safe assets such as government bonds. This saw Vanguard UK Government Bond detract from performance in November.

OUTLOOK

While the news of effective coronavirus vaccines is positive, the time it will take to deploy the vaccines and for economies and societies to reopen, should not be underestimated. And with many countries still grappling with rising cases and returning to lockdowns, economic conditions will not return to how they were before for some time. In the immediate term, international trade flows and supply chains have been permanently disrupted in places; balance sheets will be damaged, requiring gradual repair or rights issues; dividends will be under threat and share buybacks reduced.

In the longer term, technology disruption will accelerate; consumer attitudes will be very cautious; collectively, governments will be less able to stimulate recovery than after the financial crisis; weaker economic growth will leave some companies struggling to grow sales and profits; investors will be more aware, and cautious, of social and environmental 'negative externalities' and poor corporate governance; affected shares will trade on lower valuations. For all these reasons, it is a time to remain vigilant and not to be complacent. Our focus will remain on investments that can generate secure and growing cashflows over the long term.

In the immediate term, any positive economic momentum and supportive fiscal spending will provide an impulse to corporate earnings. Monetary spending (e.g. QE) and interest rates at the zero bound will allow refinancing opportunities for companies to invest at more affordable levels. In addition, there are numerous opportunities driven by the shift to a more digital world, in new automation, climate change mitigation and adaptation, demographic trends and by shifts in consumption patterns in both the emerging and the developed markets. These themes can surpass the broad measures of GDP growth and the challenges triggered by the coronavirus.



IMPORTANT INFORMATION

If you are a private investor, you should not act or rely on this document but should contact your professional advisor.

This document has been approved by Sarasin & Partners LLP of Juxon House, 100 St Paul's Churchyard, London, EC4M 8BU, a limited liability partnership registered in England & Wales with registered number OC329859 which is authorised and regulated by the Financial Conduct Authority with firm reference number 475111 and passported under MiFID to provide investment services in the Republic of Ireland.

It has been prepared solely for information purposes and is not a solicitation, or an offer to buy or sell any security. The information on which the document is based has been obtained from sources that we believe to be reliable, and in good faith, but we have not independently verified such information and no representation or warranty, express or implied, is made as to their accuracy. All expressions of opinion are subject to change without notice.

The investments of the model portfolios are subject to normal market fluctuations. **The value of the investments of the model portfolios and the income from them can fall as well as rise and investors may not get back the amount originally invested.** If investing in foreign currencies, the return in the investor's reference currency may increase or decrease as a result of currency fluctuations. **Past performance is not a guide to future returns and may not be repeated.**

Neither Sarasin & Partners LLP nor any other member of the Bank J. Safra Sarasin group accepts any liability or responsibility whatsoever for any consequential loss of any kind arising out of the use of this document or any part of its contents. The use of this document should not be regarded as a substitute for the exercise by the recipient of his or her own judgment. Sarasin & Partners LLP and/or any person connected with it may act upon or make use of the material referred to herein and/or any of the information upon which it is based, prior to publication of this document. If you are a private investor you should not rely on this document but should contact your professional adviser.

© 2020 Sarasin & Partners LLP – all rights reserved. This document can only be distributed or reproduced with permission from Sarasin & Partners LLP.

SARASIN & PARTNERS LLP

Juxon House, 100 St. Paul's Churchyard
London EC4M 8BU

T +44 (0)20 7038 7037
www.sarasinandpartners.com

